香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立正 達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《2025年度利潤分配方案公告》，僅供 參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2026年3月31日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；本公 司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 重要内容提示： 一、利润分配方案 ...

Key Points - The article highlights the latest developments of Sequoia Medical member companies showcased at the 2026 Zhongguancun Forum, emphasizing their innovative products and collaborations [3] Group 1: Innovations in Medical Technology - Zhiran Medical launched a groundbreaking 100-channel invasive brain-machine interface system, recognized for its technological advancements, marking a significant step in the high-bandwidth human-machine interaction field [5] - Aikang Medical presented its "Neuro Intervention Family Package," which includes solutions for hemorrhagic and ischemic strokes, showcasing its evolution from a tech newcomer to an industry leader [7] - Qianglian Zhichuang introduced the DEEP AI for NEURO series, an AI catheter shaping robot, representing a significant innovation in the intelligent diagnosis and treatment of neurovascular diseases [10] Group 2: Strategic Collaborations and Approvals - Incyte announced a global research collaboration with Eli Lilly, with a total transaction value potentially reaching $27.5 billion, focusing on the discovery and development of new therapies [6][15] - Borui Kang's invasive brain-machine interface product received regulatory approval, facilitating its transition from approval to clinical application, addressing the needs of patients with spinal cord injuries [16][18] - Blood Xiji Bio's innovative platelet-reducing drug received two IND approvals within ten days, highlighting its potential in treating various causes of thrombocytopenia [23][24] Group 3: Expanding Product Offerings - Jingfeng Medical's single-port laparoscopic surgical robot received approval for expanded use across four major surgical fields, enhancing its competitive edge in the surgical robotics market [25] - Weike Medical's transcatheter aortic valve replacement system was selected for the NMPA's priority review list, indicating its significant clinical application value and potential for expedited approval [28] - Orka launched the world's first ANC hearing aid in collaboration with Bose, integrating advanced noise-cancellation technology to improve user experience [19][21] Group 4: Industry Growth and Investment - Sequoia China has invested in over 250 high-growth medical health companies, covering various sectors including innovative drugs, medical devices, and digital healthcare, with more than 50 companies successfully completing IPOs [30]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立正 達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《2025年年度報告摘要》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2026年3月31日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；本公 司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 北京市春立正达医疗器械股份有限公司202 ...

Financial Performance - Total revenue for 2025 was 33.282 billion CNY, a year-on-year decrease of 9.38% [3] - Net profit for 2025 was 8.451 billion CNY, down 28.01% year-on-year [3] - Operating cash flow for 2025 was 10.145 billion CNY, a decline of 18.40% year-on-year [3] - Q4 2025 revenue was 7.448 billion CNY, showing a growth of 2.86% year-on-year [4] - Q4 2025 net profit was 0.638 billion CNY, a decrease of 38.54% year-on-year [4] Shareholder Returns - Cumulative dividends since the 2018 IPO reached approximately 37.336 billion CNY, over 6 times the IPO fundraising amount [5] - The dividend payout ratio for 2025 was 65.27% [5] - Total dividends distributed in 2025 amounted to 5.310 billion CNY [5] Market Performance International Market - International revenue was 17.650 billion CNY, accounting for 53% of total revenue, with a year-on-year growth of 7.40% [6] - The European market saw a growth of approximately 17% [6] - Emerging business sectors grew by around 30% [6] Domestic Market - Domestic revenue was 15.632 billion CNY, representing 47% of total revenue, with a year-on-year decline of 22.97% [7] - Positive growth is expected in the domestic market for 2026 [7] Business Segments - Emerging business revenue was 5.378 billion CNY, with a year-on-year growth of 38.85% [8] - Medical imaging revenue was 9.837 billion CNY, down 18.02% year-on-year [8] - Life information and support business revenue was 5.717 billion CNY, down 19.80% year-on-year [8] Innovation and R&D - R&D accounted for 11.80% of total revenue, totaling 3.929 billion CNY [18] - The company applied for a total of 12,983 patents, with 6,567 granted [18] Strategic Developments - The company aims to enhance its international presence and localize its operations to adapt to market changes [31] - Strategic partnerships are being developed to strengthen its position in the global healthcare market [31]

Group 1: Sustainable Development Strategy - Mindray's sustainable development strategy focuses on six key areas, integrating sustainability into every aspect of its value chain to contribute to a healthier future [1] - The company has received multiple awards in sustainable development for 2025, including recognition from the China Listed Companies Association and Wind ESG ratings [1] Group 2: ESG Ratings and Compliance - Mindray achieved an MSCI ESG rating of AA and a CDP climate change questionnaire score of B [1] - The company maintains a 100% compliance training coverage rate for employees and has zero confirmed corruption incidents or litigation cases [1] Group 3: Research and Development - R&D investment reached CNY 3.929 billion, with 5,212 R&D engineers, accounting for 24.48% of total employees; 66.21% of R&D personnel hold a master's degree or higher [5] - Mindray has filed a total of 12,983 patents, including 9,399 invention patents, and has authorized 6,567 patents, with 3,409 being invention patents [5] Group 4: Quality Management and Green Development - The company has undergone 251 quality management system audits with a 100% pass rate, and all production bases are certified under ISO 9001 or ISO 13485 [9] - Mindray aims to reduce carbon emissions intensity by 25% by 2030 compared to 2021 levels, with a 9.1% reduction target for 2025 [10] Group 5: Employee Development and Diversity - Mindray employs 21,288 staff globally, with 17.28% being foreign employees; 34.80% of the workforce are women, and 26.90% of R&D positions are held by women [15] - The company has a 100% training coverage rate for employee health and safety management [15] Group 6: Community Engagement and Philanthropy - Mindray's initiatives include screening 312 cleft lip and palate patients in Yunnan, providing free surgeries for 189 cases, and raising over CNY 72,000 for Smile Action [17] - The company has committed to training 480,000 people in emergency response by 2025 and has successfully treated 427 cardiac arrest patients using its AED devices [19] Group 7: Future Vision - Mindray aims to drive high-quality development through technological innovation, ecological collaboration, and global expansion to enhance healthcare access [20]

Financial Data and Key Metrics Changes - For the full year 2025, RenovoRx generated over $1 million in revenue, with fourth quarter revenues at $238,000, reflecting strong initial adoption of RenovoCath [6][20] - Gross profit for Q4 was $210,000, resulting in a gross margin of 88% [21] - Research and development expenses for Q4 were $1.5 million, totaling $6.3 million for the year, indicating continued investment in clinical trials [21] - Selling, general, and administrative expenses for Q4 were $2.2 million, with a total of $7 million for the year, reflecting disciplined cost management [21] Business Line Data and Key Metrics Changes - The company exited Q4 with nine active commercial centers, with three becoming active in the last two weeks of the year [7] - As of February 27, 2026, 12 U.S. cancer centers are utilizing RenovoCath, with 21 additional centers evaluating the device, representing a tripling of the near-term pipeline compared to Q1 2025 [9] Market Data and Key Metrics Changes - The company expects to target approximately 36 active commercial sites by year-end 2026, tripling the current footprint of 12 [10][24] - The growth in active commercial sites is expected to drive revenue growth, with a projected revenue range of $3 million to $4 million for 2026 [25] Company Strategy and Development Direction - RenovoRx is focused on scaling its commercial operations and expanding its active site network, supported by a robust pipeline of centers [10][24] - The company aims to deepen utilization at existing sites while expanding its commercial footprint, which is expected to be the primary driver of revenue growth [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial viability of RenovoCath, highlighting strong physician demand and ongoing clinical validation through the TIGeR-PaC trial [10][15] - The company is optimistic about the momentum generated in early 2026, with expectations for Q1 to be the strongest revenue quarter yet [23][24] Other Important Information - The company closed an oversubscribed private placement on March 23, 2026, resulting in gross proceeds of approximately $10 million, providing financial flexibility for commercial scale-up [22] - The TIGeR-PaC trial is on track, with 104 patients randomized as of March 24, 2026, and final data anticipated in 2027 [16] Q&A Session Summary Question: Transitioning TIGeR-PaC centers to commercial customers - Management indicated that transitioning existing TIGeR-PaC centers to commercial customers is simpler due to established familiarity and training, with most centers already having pricing agreements in place [29] Question: Catheter outlook and revenue expectations - Management refrained from providing specific guidance but indicated strong growth potential in Q1 based on early 2026 site activity and orders [33][35] Question: Clarification on active centers - Management clarified that 12 centers are currently active, with 21 additional centers in the approval process, and emphasized the importance of completing enrollment in the TIGeR-PaC trial for future commercial activity [41][52] Question: G&A expenses outlook - Management expects G&A expenses to remain around $2.2 million for Q4, with slight increases as additional sales personnel are added [42][44]

微創醫療科學有限公司* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 1 股東及投資者請注意，以上心脈醫療科技財務資料根據中國會計準則編製，並僅與心脈醫療科技的 業務有關，而與本集團其他附屬公司無關。該等(a)並未撇除集團內交易，(b)並不包括本集團所有業 務，及(c)並不代表或全面反映本集團業務或狀況。 （於開曼群島註冊成立的有限公司） （股份代號：00853） 上海微創心脈醫療科技（集團）股份有限公司 截至二零二五年十二月三十一日止十二個月經審核財務資料 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年十二月 三十一日止十二個月的經審核財務資料。本集團持有心脈醫療科技40.32%的股權，其業績於本公司 財務報表合併入賬。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至二零二五年 | 截至二零二四年 | | | --- | --- | --- | --- | | | 十二月三十一日止 | 十二月三十一 ...

Market Overview - The North Exchange A-shares market is experiencing increased risk aversion due to ongoing global geopolitical conflicts and fluctuating expectations of interest rate cuts by the Federal Reserve, leading to heightened volatility in global risk assets[6] - The average daily trading volume in the A-share market has decreased by CNY 100.6 billion, while the North Exchange A-shares' average daily trading volume has shrunk by CNY 28.7 billion, reaching a near one-year low[6] Valuation and Performance - The current PE (TTM) ratio for North Exchange A-shares has dropped to approximately 34 times, down from about 50 times in mid-2025, indicating a significant correction[6] - The North Exchange's valuation is now lower than that of the Sci-Tech Innovation Board (42.2 times) and the Growth Enterprise Market (38.0 times), suggesting a growing safety margin for long-term investments[6] Trading Activity - As of March 27, 2026, the North Exchange A-shares consist of 301 stocks with an average market capitalization of CNY 26.8 billion, compared to CNY 131.1 billion for the Growth Enterprise Market and CNY 187.2 billion for the Sci-Tech Innovation Board[13] - The total trading amount for the North Exchange during the week was CNY 677.6 billion, with an average trading amount per stock of CNY 2.2 billion and a turnover rate of 15.9%[13] Stock Performance - In the recent trading period, the North Exchange 50 index fell by 3.4%, underperforming the Growth Enterprise Market by approximately 1.7 percentage points[20] - Among the 301 stocks, 28 stocks increased in value, while 272 stocks decreased, with the top performer, Puan Medical, rising by 136.6%[22] New Listings - One new stock, Puan Medical (920069.BJ), was listed on March 27, 2026, with a first-day increase of 136.6% and a PE ratio of 15.0 times[30] - Upcoming listings include three companies: Yuelong Technology, Sain Electronics, and Longyuan Co., with expected issuance prices and PE ratios ranging from 13.8 to 15.0 times[34] Risk Factors - Key risks include policy changes, liquidity risks, and the potential for corporate earnings to fall short of expectations, which could further impact market sentiment[6]

Financial Performance - In 2025, the company achieved operating revenue of CNY 1.886 billion, a year-on-year increase of 20.93% [3] - The net profit attributable to shareholders was CNY 68.54 million, a decrease of 40.62%, primarily due to adjustments related to the acquisition of Saint Nor [3] - Excluding non-recurring items, the net profit attributable to shareholders increased by 28.50% to CNY 107 million [3] - The net cash flow from operating activities was CNY 341 million, up 31.47% year-on-year [3] Medical Services - The medical services segment generated revenue of CNY 1.501 billion, with a patient volume of 604,100, reflecting an 11% year-on-year growth [4] - Surgical volume increased by 71%, with advanced surgeries (level 3 and 4) accounting for 78% of total surgeries, up 7 percentage points [4] - The company completed a strategic acquisition of Changsha Kexin Tumor Hospital, contributing CNY 622 million to tumor business revenue, which represented 41.5% of medical service income [3][4] Technological Innovation - The company has integrated AI capabilities into key diagnostic and treatment processes, reducing preoperative planning time by approximately 80% and decreasing postoperative hospital stays by 1.5 days [7] - AI-enabled services have achieved a patient Net Promoter Score (NPS) of 93%, surpassing the industry average of 90% [7] Medical Devices - The medical device segment reported revenue of CNY 380 million, a year-on-year increase of 14.30% [9] - The acquisition of Saint Nor and Uni Medical exceeded performance targets, with Saint Nor achieving a net profit of CNY 87.40 million, a completion rate of 127.47% for performance commitments [10] - The overseas revenue for medical devices reached CNY 104 million, up 20.24% year-on-year [10] Strategic Development - The company plans to continue expanding its regional medical center layout and pursue "ecological mergers" to enhance synergy [20] - Focus areas for future acquisitions include imaging enhancement, tumor treatment, life support, and blood circulation [20] - The company is also developing a comprehensive health management platform for cancer patients, which is currently in the testing phase [12]

Group 1: Financial Performance - The company is expected to maintain a revenue growth rate of 30% and a profit growth rate of 40% in 2026[1] - The projected net profit for 2026 is 499 million yuan, reflecting a 43% increase from 2025[1] - The earnings per share (EPS) is forecasted to reach 2.3 yuan in 2026, up from 1.6 yuan in 2025[1] Group 2: Market Expansion - The company's overseas market share is anticipated to increase to 30% in 2026, driven by new product registrations in Europe[1] - The acquisition of Yijie Medical is expected to enhance the company's capabilities in the neurosurgery market, contributing to revenue growth[1] Group 3: Industry Trends - The electronics sector is experiencing a positive trend, with TCL's TV business showing significant growth in both domestic and international markets[1] - The chemical industry is benefiting from rising oil prices and a tightening supply chain, which is expected to enhance profit margins for companies like Satellite Chemical[1] Group 4: Risks and Challenges - There are risks associated with intensified market competition and potential trade frictions affecting international sales[1] - The company faces challenges related to raw material price volatility and the impact of geopolitical tensions on oil prices[1]